Trial Condition(s):

Cardiovascular Abnormalities

Magnevist® Injection enhanced MRA compared to non contrast MRA for the detection of structural abnormalities of the aortic arch and cerebral branches

Bayer Identifier:

90941

ClinicalTrials.gov Identifier:

NCT00310609

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of Magnevist (the study drug) used for MRI of the aortic arch and cerebral branches. The results will be compared to the results of MRI taken without Magnevist, and with the results of your X-ray angiography.

Inclusion Criteria
- Has known or suspected disease of the aortic arch and cerebral branches
 - Is scheduled for X-ray angiography
Exclusion Criteria
- Has any contraindication to magnetic resonance imaging
 - Is scheduled for any procedure before the X-ray angiography
 - Had previous bilateral intervention (surgery, bypass) of the arteries of interest

Trial Summary

Enrollment Goal
123
Trial Dates
black-arrow
Phase
3
Could I receive a placebo?
No
Products
Magnevist (Gadopentetate Dimeglumine, BAY86-4882)
Accepts Healthy Volunteers
No

Where to Participate

Locations
Status
LocationsStatus

Trial Design